Eldridge J Charles, Stevens James T, Breckenridge Charles B
Department of Physiology and Pharmacology, Wake Forest University School of Medicine, Winston-Salem, NC 27157-1083, USA.
Rev Environ Contam Toxicol. 2008;196:147-60. doi: 10.1007/978-0-387-78444-1_6.
More than 40 publications have described results of atrazine responses in 17 estrogen-dependent systems and in more than a dozen different reporter and estrogen receptor-binding studies in vitro. Results from these studies have consistently failed to demonstrate that atrazine acts as an estrogen agonist. Moreover, a variety of indices of estrogen-dependent activity, in models that encompass cell incubations to whole animals, have failed to respond to atrazine. Researchers in more than a dozen laboratories have examined rats, rat tissues, human and prokaryotic cells, in addition to tissues from reptile, fish, amphibian, avian, molluscan, and insect sources, without eliciting estrogenic-like responses from atrazine. In contrast, studies of atrazine ability to antagonize estrogen-mediated responses have yielded equivocal results. Results of several studies show inhibition of estrogen-like activities by atrazine, yet many other tests have yielded negative results. Generally, in vivo models have more consistently shown that atrazine inhibits estrogen-mediated responses, whereas in more specific in vitro systems, inhibition is seldom observed. The implication is that in vivo effects of atrazine may result from inhibition of factors that are indirectly connected to the genomic interaction of estrogen (e.g., at the receptor). Potential targets of atrazine may be downstream of the ligand-receptor binding event. Atrazine may also interact with other, less specific, factors that are necessary for the completion of the estrogen-mediated response. Moreover, the apparent inhibition of cytosolic-ER binding by atrazine may, similarly, be relatively nonspecific. Observed inhibitory responses occur only at extreme doses or concentrations, i.e., several orders of magnitude greater than the level of estradiol presence in each test system. It is probable that the inhibitory effects result from very low affinity and/or low specificity interactions, which are unlikely to occur in nature. We conclude that atrazine is not an estrogen receptor agonist, but it may be a weak antagonist, when present at a high concentration under conditions of disequilibrium with estrogen. These conditions are not expected to occur as a result of normal environmental exposure.
40 多篇出版物描述了阿特拉津在 17 种雌激素依赖性系统中的反应结果,以及在体外进行的十多项不同的报告基因和雌激素受体结合研究的结果。这些研究结果一直未能证明阿特拉津具有雌激素激动剂的作用。此外,在从细胞培养到完整动物的各种模型中,多种雌激素依赖性活性指标对阿特拉津均无反应。除了来自爬行动物、鱼类、两栖动物、鸟类、软体动物和昆虫的组织外,十几个实验室的研究人员还对大鼠、大鼠组织、人类和原核细胞进行了检测,均未发现阿特拉津引发类似雌激素的反应。相比之下,关于阿特拉津拮抗雌激素介导反应能力的研究结果却模棱两可。几项研究结果显示阿特拉津可抑制雌激素样活性,但许多其他测试结果却为阴性。一般来说,体内模型更一致地表明阿特拉津会抑制雌激素介导的反应,而在更具体的体外系统中,很少观察到抑制作用。这意味着阿特拉津的体内效应可能是由于抑制了与雌激素基因组相互作用间接相关的因素(例如,在受体水平)。阿特拉津的潜在靶点可能在配体 - 受体结合事件的下游。阿特拉津还可能与雌激素介导反应完成所需的其他不太特异的因素相互作用。此外,阿特拉津对胞质雌激素受体结合的明显抑制作用可能同样相对不特异。观察到的抑制反应仅在极高剂量或浓度下出现,即比每个测试系统中雌二醇的存在水平高出几个数量级。这种抑制作用可能是由于极低的亲和力和 / 或低特异性相互作用导致的,而这种情况在自然环境中不太可能发生。我们得出结论,阿特拉津不是雌激素受体激动剂,但在与雌激素不平衡的条件下高浓度存在时,它可能是一种弱拮抗剂。正常环境暴露不太可能导致这些条件出现。